Navigation Links
Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
Date:6/21/2013

SAN DIEGO and IRVINE, Calif., June 21, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq™) and IG-004 (TOCOSOL® paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) in Basel, Switzerland on June 23 - 26. Sorrento has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013.

IGDRASOL'S data mining of the clinical data for both IG-001 and IG-004 has generated exciting insights into the field of nanomedicine, which will be presented at the joint meeting. These findings are highly relevant to the theme of this year's conference, namely "Nanomedicine & Targeted Medicine – the paradigm of precise, highly effective and innocuous medicine for the benefit of patients and mankind".

IG-001 (Cynviloq™) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM®. It has completed Phase 1 or 2 trials in metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and bladder cancer in the U.S. and/or ex-U.S. IGDRASOL is preparing for an "End of Phase 2" meeting scheduled with the U.S. Food & Drug Administration (FDA) in July 2013, regarding the clinical development of Cynviloq™. As an injectable nanoparticle formulation of paclitaxel, Cynviloq™ may be eligible for approval through the FDA's 505(b)(2) bioequivalence regulatory pathway versus albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) in its currently approved MBC and NSCLC ind
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
2. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
3. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
6. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
7. Sorrento Therapeutics Awarded Third Phase I STTR Grant
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical company ... in the U.S. and XIAPEX ® in the ... will present at the following upcoming investor conferences. ... Renshaw 16 th Annual Global Investment Conference ( ... at 9:10 a.m. EDT , Aegis Capital 2014 ...
(Date:9/2/2014)... 2, 2014  MEI Pharma, Inc. (Nasdaq: ... the clinical development of novel therapies for cancer, ... a randomized Phase II clinical trial of its ... azacitidine in patients with previously untreated intermediate-2 or ... study enrolled a total of 108 patients with ...
(Date:9/2/2014)... SAN ANTONIO , Sept. 2, 2014 /PRNewswire/ ... private medical technology company focused on innovating lifesaving ... announced the appointment of Dr. Gabriele Niederauer ... President and CEO. Following the recent closure of ... CE Mark for the Surfacer™ Inside-Out Access Catheter ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 3MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 4Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO 2
... Inc. ( www.hydrocision.com ), a privately held medical ... majority of the Company by new investors, led ... Omega Funds. HydroCision is the developer, manufacturer, and ... allows discectomy and interbody fusion procedures to be ...
... CITY, Sept. 15 Amedica Corporation, a spinal and ... nitride (SiN) ceramic technologies, announced today that it has ... disc replacement (TDR) technology that features the use of ...  U.S. Patent No. 7,758,646 B2 and U.S. Patent No. ...
Cached Medicine Technology:HydroCision Announces New Investment to Accelerate Growth of Novel Fluidjet Technology for Minimally Invasive Spine Surgery 2Amedica® Receives Patents for Innovative Motion-Preserving Total Disc Implant Featuring Silicon Nitride 2
(Date:9/2/2014)... (PRWEB) September 02, 2014 - Molecular ... as a class of diagnostic test that analyzes proteins ... nucleic acids and proteins that belong to individual patients ... health condition, or risk of developing a specific disease. ... known as (MDx) evaluating the new class of diagnostic ...
(Date:9/2/2014)... A little white pill may help scientists learn ... than their peers, even if their lungs are relatively ... marketed as Revatio to treat pulmonary hypertension and ... cocktail of over-the-counter antioxidants will help them identify the ... difficult for these patients. , "We want to ...
(Date:9/2/2014)... The Society of Nuclear Medicine and Molecular Imaging (SNMMI) ... SNMMI Wagner-Torizuka Fellowship. This two-year fellowship, founded in 2008 ... the late Kanji Torizuka, MD, PhD, is designed to ... nuclear medicine and molecular imaging for Japanese physicians in ... "SNMMI is proud to sponsor the Wagner-Torizuka Fellowship. This ...
(Date:9/2/2014)... 2014 Vertebral invasive compression fractures called ... vertebrae in our spine suffers crack or gets deformed. ... in people with osteoporosis or low bone density. Though ... forms of metastatic tumors and extensive trauma such as ... can also lead to such fractures. , The placement ...
(Date:9/2/2014)... 02, 2014 Concorde Career College ... to receive the 2014 Excellence in Community Service ... and Colleges (ACCSC). , Every year, the Accrediting ... members who make outstanding contributions in their local ... for the scope and impact of the community ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 2Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 3Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 4Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:SNMMI 2014-2016 Wagner-Torizuka Fellowship recipients announced 2Health News:An Overview of the Minimally Invasive Vertebral Compression Fracture Repair Market by Transparency Market Research 2Health News:An Overview of the Minimally Invasive Vertebral Compression Fracture Repair Market by Transparency Market Research 3Health News:Concorde Career College North Hollywood Awarded 2014 Excellence in Community Service Award 2
... HealthDay Reporter , TUESDAY, July 27 (HealthDay News) -- ... lost? Seeking out the right Web site might help, a ... logged on to a specially designed Internet site for weight maintenance ... loss than people who logged on less often, new research finds. ...
... HealthDay Reporter , MONDAY, July 26 (HealthDay News) -- An ... to help severely disabled people play computer games, express themselves ... experimental "sniff controller" takes advantage of the fact that cranial ... still able to send messages to the soft palate (the ...
... (BRONX, NY) For the third time in four months, ... the National Institutes of Health (NIH) has awarded Albert Einstein ... at helping people infected with multidrug-resistant tuberculosis (MDR-TB). ... The latest awardee Neel Gandhi, M.D. , assistant ...
... that patients often exhibit a significant decrease in weight and body ... The study is the first of its type to correct ... between the ages of 29 to 73 years. The study ... of 196 Mount Sinai patients who had knee or hip replacement ...
... What,s a baseball game or a football game or a ... offer a staggering array of food from appetizers to desserts. But ... beer. A special news media briefing and reception will focus ... 240th National Meeting & Exposition , which be held here ...
... 2010) A major research company affiliated with the ... is partnering with the University of Colorado,s Anschutz Medical ... discoveries from the laboratory to the patient. CPC, formally ... the University Physicians Incorporated building across the street from ...
Cached Medicine News:Health News:To Help Keep Weight Off, Turn to the Web 2Health News:To Help Keep Weight Off, Turn to the Web 3Health News:Sniffing Device Allows Disabled to Write, Run Wheelchairs 2Health News:Sniffing Device Allows Disabled to Write, Run Wheelchairs 3Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 2Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 3Health News:Many knee and hip replacement patients experience weight decrease after surgery 2Health News:Special news media briefing and reception during American Chemical Society national meeting 2Health News:University of Colorado joins forces with major research affiliate 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: